Antineoplastic Effects of Ankaferd Hemostat

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Ankaferd Blood Suppressor (ABS) influences critical cellular processes including cell cycle control, apoptosis, angiogenesis, and metabolic mechanisms.
• The molecular underpinnings of ABS's antineoplastic activity involve its proteomic, metabolomic, and transcriptomic profiles.

Purpose of the Study:

• To review the antineoplastic effects of Ankaferd Blood Suppressor (ABS) on various cancer types.
• To explore the potential therapeutic applications of ABS in cancer treatment and supportive care.

Main Methods:

• Literature searches were conducted using Medline, Google Scholar, and Embase up to June 2022.
• A PRISMA flow diagram was utilized to describe the search methodology for Ankaferd.

Main Results:

• ABS demonstrates antineoplastic effects against solid tumors (colon, bladder, breast, osteosarcoma, melanoma, hepatocellular carcinoma) and hematological malignancies (myeloma, lymphoid cells).
• ABS impacts renal tubular apoptosis, inhibits mesenchymal stem cells, and has antiproliferative effects on gastrointestinal tumors.
• ABS offers supportive roles in cancer care by preventing DNA damage, reducing intestinal injury, and possessing chemopreventive and hepatoprotective properties, including prophylaxis for oral mucositis.

Conclusions:

• ABS alters cell metabolism and cell cycle, contributing to its antineoplastic role.
• The therapeutic scope of ABS extends to anti-infective and wound-healing properties, with potential for palliative, adjuvant, or neoadjuvant use.
• Further controlled studies are essential to elucidate the pleiotropic effects of ABS, including its antineoplastic, antithrombotic, anti-inflammatory, anti-infective, antifungal, and antioxidative capabilities.